Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety analysis of luteolin for prostate cancer patients on active surveillance
jRCTs041230029Active, not recruiting
- Start
- Jun 2023
- Modality
- Classical Binding Small Molecules → Small Molecules, Covalent Small Molecules → Small Molecules, Nucleic Acid-Directed Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Open-label, single-arm trial of luteolin in prostate cancer (PCa). Primary endpoint: Incidence and severity of adverse events. Started Jun 2023; status: active, not recruiting.
02
Drugs
luteolin
03
Conditions
prostate cancer (PCa)
Beyond the preview
Go deeper on jRCTs041230029.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCTs041230029.